Last update 01 Nov 2024

Kashiv Biosciences Pvt Ltd.

Subsidiary Company|

India

Subsidiary Company|

India

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with Kashiv Biosciences Pvt Ltd.

CTRI/2024/08/072953 / Not yet recruitingPhase 3

A Multicenter, Open-Label, Single-Arm, Two-Cohort, Phase 3, Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Eliglustat Sublingual Film in Patients with Gaucher Disease Type 1. - NIL

Start Date02 Sep 2024

Sponsor / Collaborator

Kashiv Biosciences Pvt Ltd.

CTRI/2020/09/028030 / CompletedNot Applicable

A randomized, assessor-blind, multi-center, three-treatment, parallel group study comparing two test formulations of Bimatoprost ophthalmic solution 0.01% of Kashiv BioSciences with LUMIGANÂ® (Bimatoprost ophthalmic solution) 0.01% of Allergan, Inc., Irvine, CA 92612, U.S.A in patients with chronic open-angle glaucoma or ocular hypertension in both eyes.

Start Date28 Sep 2020

Sponsor / Collaborator

Kashiv Biosciences Pvt Ltd.

100 Clinical Results associated with Kashiv Biosciences Pvt Ltd.

0 Patents (Medical) associated with Kashiv Biosciences Pvt Ltd.

Literatures (Medical) associated with Kashiv Biosciences Pvt Ltd.

01 Jun 2024·Chemistry & Biodiversity

Computational Exploration of Naturally Occurring Flavonoids as TGF‐β Inhibitors in Breast Cancer: Insights from Docking and Molecular Dynamics Simulations and In‐vitro Cytotoxicity Study

Article

Author: Shah, Umang ; Patel, Niyati ; Rohit, Shishir ; Patel, Vishwa ; Jawarkar, Rahul D ; Patel, Mehul ; Patel, Swayamprakash ; Solanki, Nilay ; Patel, Ashish ; Patel, Rajvi

AbstractBreast cancer is a global health concern, demanding innovative treatments. Targeting the Transforming Growth Factor‐beta (TGF‐β) signaling pathway, pivotal in breast cancer, is a promising approach. TGF‐β inhibits proliferation via G1 phase cell cycle arrest, acting as a suppressor initially, but in later stages, it promotes progression by enhancing motility, invasiveness, and metastasis formation. This study explores naturally occurring flavonoids′ interactions with TGF‐β. Using molecular docking against the protein‘s crystal structure (PDB Id: 1PY5), Gossypin showed the highest docking score and underwent molecular dynamics simulation, revealing complex flexibility and explaining how flavonoids impede TGF‐β signaling in breast cancer. ADMET predictions adhered to Lipinski's rule of Five. Insights into flavonoid‐TGF‐β binding offer a novel angle for breast cancer treatment. Flavonoids having a good docking score like gossypin, morin, luteolin and taxifolin shown potent cytotoxic effect on breast cancer cell line, MCF‐7. Understanding these interactions could inspire flavonoid‐based therapies targeting TGF‐β to halt breast cancer growth. These findings pave the way for personalized, targeted breast cancer therapies, offering hope against this formidable disease.

01 Jan 2024·Bioprocess and Biosystems Engineering

Highly purified charge variants of a proposed biosimilar to Omalizumab: impact on in vitro potency and stability under thermal stress

Article

Author: Gupta, Tarun ; Seshadri, Sriram

Biosimilars are highly complex and similar biological drugs are developed with different manufacturing processes which are not similar to originator manufacturing process. Due to this, biosimilar products inherently have quality differences in comparison to innovator molecule which may be related to size, charge and glycosylation. Despite these differences they are supposed to demonstrate similar behaviour in safety and efficacy profile to the reference product and these differences should not be clinically meaningful. Charge variants are one of the critical quality attributes and sources of heterogeneity. In this study, highly purified charge variants cluster (acidic, main peak and basic) of biosimilar product of Xolair were assessed for their impact on in vitro potency and stability at different thermal stress conditions (2-8 °C and - 20 °C). The study data indicating purified charge variants (> 90%) have no impact on in vitro potency and are stable at different thermal stress conditions up to a week.

29 Dec 2023·Journal of Biomolecular Structure and Dynamics

New molecular insights for 4 H -1,2,4-triazole derivatives as inhibitors of tankyrase and Wnt-signaling antagonist: a molecular dynamics simulation study

Article

Author: Rohit, Shishir ; Patel, Saumya ; Bhatt, Hardik G. ; Mehta, Chirag C.

Tankyrase (TNKS) enzymes remained central biotargets to treat Wnt-driven colorectal cancers. The success of Olaparib posited the druggability of PARP family enzymes depending on their role in tumor proliferation. In this work, an MD-simulation-based comparative assessment of the protein-ligand interactions using the best-docked poses of three selected compounds (two of the designed and previously synthesized molecules obtained through molecular docking and one reported TNKS inhibitor) was performed for a 500 ns period. The PDB:ID-7KKP and 3U9H were selected for TNKS1 and TNKS2, respectively. The Molecular Mechanics Generalized Born Surface Area (MM-GBSA) based binding energy data exhibited stronger binding of compound-15 (average values of -102.92 and -104.32 kcal/mol for TNKS1 and TNKS2, respectively) as compared to compound-22 (average values of -82.99 and -85.68 kcal/mol for TNKS1 and TNKS2, respectively) and the reported compound-32 (average values of -81.89 and -74.43 kcal/mol for TNKS1 and TNKS2, respectively). Compound-15 and compound-22 exhibited comparable or superior binding to both receptors forming stable complexes when compared to that of compound-32 upon examining their MD trajectories. The key contributors were hydrophobic stacking and optimum hydrogen bonding allowing these molecules to occupy the adenosine pocket by interfacing D-loop residues. The results of bond distance analysis, radius of gyration, root mean square deviation, root mean square fluctuation, snapshots at different time intervals, LUMO-HUMO energy differences, electrostatic potential calculations, and binding free energy suggested better binding efficiency for compound-15 to TNKS enzymes. The computed physicochemical and ADMET properties of compound-15 were encouraging and could be explored further for drug development.Communicated by Ramaswamy H. Sarma.

100 Deals associated with Kashiv Biosciences Pvt Ltd.

100 Translational Medicine associated with Kashiv Biosciences Pvt Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Kashiv Biosciences Pvt Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 22 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing